Antibacterial Agents TRIZ Cases

Composite polymer particles present multiple tuberculosis antigens simultaneously, resolving low diagnostic sensitivity and specificity in conventional tests.

Structural mimetics replicate proline-rich peptide conformations to resist proteolytic degradation while maintaining high affinity for target protein domains.

Developing Form IV and V via aliphatic ketone dissolution resolves limited bioavailability in amorphous minocycline base formulations.

Measuring secretor antigens in infant biological samples identifies individuals at risk for necrotizing enterocolitis.

Formula 1 GABA derivatives bind alpha2δ-1 subunits to treat neuropathic pain while extending half-life and reducing dosing frequency.

IgM-enriched immunoglobulin preparation reduces 28-day mortality and ventilator-free days despite broad-spectrum antibiotic limitations.

A pharmaceutical composition using a gelled aqueous phase and lipid nanocapsules to deliver antibiotics directly to infection sites.

Selective glucocorticoid mimetics dissociate transactivation from transrepression, reducing metabolic side effects while maintaining therapeutic benefits.

Saponins and medium chain fatty acids synergistically eliminate methanogenic bacteria, reducing greenhouse gas emissions while preserving nutrient availability.

Optimizing chlorhexidine concentration with pentane-1,5-diol achieves synergistic antimicrobial action while reducing skin irritation risks.

1-aza-bicyclononane derivatives target nicotinic-alpha 7 receptors to address efficacy gaps in monotherapy-refractory central nervous system disorders.

Phosphorylated dihydroxy-pentane-dione analogs disrupt bacterial quorum sensing pathways to inhibit biofilm formation.

An oily vehicle suspension of penethamate hydroiodide combined with surfactants resolves the trade-off between storage stability and rapid absorption.

Soluble chitosan derivatives dissolve in neutral solutions to clump and kill MRSA, overcoming antibiotic resistance.

Antibody-antibiotic conjugates deliver sitafloxacin to wall teichoic acid on Staphylococcus aureus for targeted intracellular bacterial elimination.

Inhaled acidic fluid with pH below 3.0 reduces pathogen load in the respiratory tract, addressing broad-spectrum antimicrobial needs without systemic toxicity.

Acidic hydrolysis of olive residues yields high-purity hydroxytyrosol without organic solvents.

Amphipathic peptides disrupt bacterial cell membranes via hydrophobic interactions, eliminating antibiotic-resistant bacteria and biofilms.

Formula I compounds selectively inhibit IRAK4 and IRAK1 kinases, controlling inflammation without increasing infection susceptibility.

Recombinant polypeptides stimulate specific immune reactions to reduce infective loads of drug-resistant Mycobacterium avium subspecies paratuberculosis.

An IL-1α-targeting antibody reverses lean body mass loss, extending survival where nutritional support fails to preserve muscle.

Formula I compounds disrupt bacterial signal transduction pathways to restore antibiotic sensitivity in drug-resistant Gram-negative bacteria.

Nucleic acid amphiphiles self-assemble into complex nanostructures like nanotubes and twisted nanotapes.

Cationic proteins neutralize Clostridium difficile toxins to prevent tissue damage after antibiotic therapy reduces bacterial load.

Salmonella Typhi Ty21a carrying an htrA-driven F1-V plasmid overcomes inadequate pneumonic plague protection via oral delivery.

A gold and graphene nanocomposite mixture delivers synergistic antimicrobial activity through photothermal conversion.

Polyimino ketoaldehyde compounds treat multi-resistant bacteria by disrupting membranes and cross-linking proteins, overcoming standard antibiotic resistance.

Liposomes encapsulate troponoids to boost solubility while eliminating solvent toxicity, enabling safe treatment of viral infections.

Fusion of Esx, PE, and PPE antigens improves solubility and folding to overcome BCG limitations in preventing TB reactivation.

Segmenting pyocins into functional domains overcomes the narrow activity spectrum of natural bacteriocins while maintaining high cytotoxicity.

Segmented lipopeptides with hydrophobic moieties target intracellular PAR2 surfaces, resolving the trade-off between effective antagonism and side effects.

AC domain peptides disrupt bacterial adhesion to prevent biofilm formation on medical surfaces.

SHIP inhibitors replace expensive IL-2 expansion protocols to sustain natural killer cell activation and IFNγ production for tumor rejection.

Fully human monoclonal antibodies bind interferon-inducible protein 10 to block receptor interaction and neutralize biological activity.

Acid-resistant capsules protect transformed microorganisms expressing flagellin antigens, enabling safe infant vaccination without pathogenic side effects.

Aptamer-NHC metal complex conjugates target cancer cells via specific receptor binding, reducing systemic toxicity from heavy metal accumulation.

Formula I compounds block USP28 and USP25 activity to address tumorigenesis and inflammation.

Targeted residue mutations in ISVDs reduce pre-existing antibody binding while maintaining CTLA-4 inhibition efficacy.

Universal epitopes in chimeric carrier proteins resolve MHC binding variability, ensuring consistent immune responses for vulnerable groups.

Formula I compounds with a fused-bicyclic moiety block the FabI enzyme, resolving inadequate treatment of bacterial infections.

Combines L-Arginine, undecylenic acid, and Rheum Officinale extract for topical application.

Topical Nu-8 compound reduces microbial burden in diabetic foot ulcers while minimizing contact irritation.

Lactic acid oligomers act as a depot to sustain low vaginal pH, preventing bacterial vaginosis recurrence and malodour.

1H-Benzimidazole-4-carboxamides with a quaternary carbon at the 2-position inhibit the PARP enzyme.

Segmenting the agent into a conjugate with a bacterial enzyme-sensitive linker directs release to disease sites, reducing toxicity to healthy tissues.

Beta-methyl substitution at position 1 enhances chemical stability and overcomes resistance in gram-negative pathogens.